Non-Steroidal Anti-Inflammatory Drugs is the class of analgesics which distinguished by their non-steroidal chemical structure. These are used to reduce pain caused due to inflammation. It is first line treatment in pain management due to their special properties such as antipyretic, analgesic, and anti-inflammatory.
Increase in bone and joint pain diseases such as osteoarthritis, and rheumatoid arthritis among individuals is the key driving factor which is expected to boost the global Non-Steroidal Anti-Inflammatory Drugs market growth. Furthermore, rise in number of surgeries will have the positive impact on market growth. Moreover, rise in geriatric population and high risk of various diseases will fuel the market growth. Also, adoption of pain management therapeutics among end users will drive the market growth during this forecast period.
Get Sample Copy of this Report @ https://qualiketresearch.com/request-sample/Non-Steroidal-Anti-Inflammatory-Drugs-Market/request-sample
However, availability of new innovative therapeutic analgesics is the major restraining factor which is expected to hamper the global Non-Steroidal Anti-Inflammatory Drugs market growth. Also, stringent government rules and regulations will affect the market growth.
Market Key Players
Various key players are discussed in this report such as GlaxoSmithKline, Johnson and Johnson, Pfizer Inc, Kopran Ltd, Bayer (DE), Abbott, Novacap (FR), Perrigo Company, and Sun Pharmaceutical Industries Ltd
- Back Pain Treatment
- Osteoarthritis Treatment
- North America
- Latin America
- Asia Pacific
- Middle East & Africa
Browse Full Research Report @ https://qualiketresearch.com/reports-details/Non-Steroidal-Anti-Inflammatory-Drugs-Market